Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds

H.      H. Zeng; L.      H. Wang

doi:10.2174/157340610793358864

Abstract

Thioredoxin reductase plays a critical role in the regulation of cancer cell apoptosis, making it an attractive target for the design of new anticancer drugs. Several classes of compounds have been considered as potential antitumor or chemopreventive agents; most of them apparently interact with thioredoxin reductases C-terminal redox center.

Keywords: Thioredoxin reductase, redox system, antitumour agents, TrxR substrates, alkylating agents, reversible TrxR inhibitor, motexafin gadolinium, ethaselen, Targeting Thioredoxin Reductase, Chemopreventive Compounds, redox homeostasis, 1,2-[bis(1,2-benzisoselenazolone-3, NADPH, TrxR1 mRNA, glutathione reductase, selenenyl-sulfide, FAD domain, Cys mutant enzyme, nucleophilic, platinum compounds, efficaciousness, Motexafin Gadolinium (MGd), Aurothioglucosea, Selenodiglutathione (GS-Se-SG), peroxidase-mimicking, Anticancer Alkylating Agents, aziridinyl quinone diaziquone, Ebselene, cytotoxicity, aurothioglucose, antiproliferative agent, Curcumin, α,β-unsaturated ketone structure, carcinogenesis, mercaptoimidazole moiety, methylseleninate, nasopharyngeal (KB), TrxR inhibition, GSH, ROS